Literature DB >> 7206587

Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.

M Eichelbaum, P Birkel, E Grube, U Gütgemann, A Somogyi.   

Abstract

A close relationship between verapamil plasma concentration and effect on P-R interval could be established both after single i.v. and oral administration and during chronic oral treatment. After i.v. administration a linear relationship between verapamil plasma concentration and delta P-R (y=x (0.74) + 1.8) with a small between subject variation in the slope of the regression (%coefficient of variation 18.7, range 0.71-1.10) was observed. The slope of the oral plasma concentration response regression (y=x (0.33)-3.0) was statistically significantly (p less than 0.05) less than the slope of the i.v. plasma level response regression. Interindividual variation in the slope was most pronounced (range 0.13 to 0.47). On average two to three times higher verapamil plasma levels were required after oral administration in order to produce the same increase in delta PR as after intravenous administration. The most plausible explanation for the different slopes of the plasma level response regression seems to be stereo-selective presystemic elimination. Since after oral administration the plasma level response curve is less steep than after i.v. administration this indicates that the more active l-isomer is preferentially metabolized during hepatic first-pass metabolism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7206587     DOI: 10.1007/bf01477049

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  15 in total

1.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide.

Authors:  R L Galeazzi; L Z Benet; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

2.  Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard.

Authors:  B Spiegelhalder; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

Review 3.  Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil.

Authors:  M R Rosen; A L Wit; B F Hoffman
Journal:  Am Heart J       Date:  1975-05       Impact factor: 4.749

4.  Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

Authors:  G Neugebauer
Journal:  Cardiovasc Res       Date:  1978-04       Impact factor: 10.787

5.  Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil.

Authors:  M Raschack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-09       Impact factor: 3.000

6.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

7.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

8.  Pharmacokinetics of verapamil in man.

Authors:  Y Koike; K Shimamura; I Shudo; H Saito
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-04

9.  Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.

Authors:  T Walle; U K Walle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-03

10.  Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.

Authors:  M Eichelbaum; H J Dengler; A Somogyi; G E von Unruh
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

View more
  28 in total

1.  Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects.

Authors:  J H Ahmed; H L Elliott; P A Meredith; J L Reid
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 2.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.

Authors:  G Stagni; A M Shepherd; Y Liu; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

4.  Pharmacodynamic modeling of digoxin-induced bradycardia.

Authors:  S J Vetticaden; W H Barr; T B Allison
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

5.  24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.

Authors:  H Mølgaard; P Bjerregaard; H S Jørgensen; N A Klitgaard
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Myocardial uptake of drugs and clinical effects.

Authors:  J D Horowitz; A C Powell
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 7.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

8.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

9.  Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.

Authors:  R Padrini; E Barbieri; D Piovan; M Toffoli; A Motta; G P Trevi; M Ferrari
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

Authors:  M Eichelbaum; G Mikus; B Vogelgesang
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.